Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer

NCT01609127 is registered in ClinicalTrials.gov with Genta Incorporated as lead sponsor.

NCT NCT01609127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Genta Incorporated
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2012
Completion date
July 31, 2014
Enrollment
213 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced non-resectable breast cancer, metastatic breast cancer